Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Kelli C. DOMINICK |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder / Logan K. WINK in Journal of Autism and Developmental Disorders, 47-7 (July 2017)
[article]
Titre : Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Logan K. WINK, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Kelli C. DOMINICK, Auteur ; Emma FOX, Auteur ; Catherine BUCK, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.2290-2294 Langues : Anglais (eng) Mots-clés : Autism Autism spectrum disorder Metformin Antipsychotic Weight gain Index. décimale : PER Périodiques Résumé : Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain. En ligne : https://doi.org/10.1007/s10803-017-3132-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314
in Journal of Autism and Developmental Disorders > 47-7 (July 2017) . - p.2290-2294[article] Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Logan K. WINK, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Kelli C. DOMINICK, Auteur ; Emma FOX, Auteur ; Catherine BUCK, Auteur ; Craig ERICKSON, Auteur . - p.2290-2294.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 47-7 (July 2017) . - p.2290-2294
Mots-clés : Autism Autism spectrum disorder Metformin Antipsychotic Weight gain Index. décimale : PER Périodiques Résumé : Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain. En ligne : https://doi.org/10.1007/s10803-017-3132-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314